Drug
Imvt 1402
Imvt 1402: highest development phase Phase 3, developed by Immunovant Sciences GmbH. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Immunovant Sciences GmbH
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMVT-1402 NCT07039916 | Phase 3 | Generalized Myasthenia Gravis |
Latest
No recent events.
Follow Imvt 1402 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.